Explore the evolving PTK7 ADC field as Genmab halts PRO1107 and Pfizer/AbbVie discontinue cofetuzumab pelidotin, while Kelun’s SKB518 advances into Phase II and Lilly joins with LY4175408 alongside Day One’s DAY301.
Discover how scientists Michael Welsh, Paul Negulescu, and Jesús “Tito” González revolutionized CF treatment with the triple-drug therapy that transformed patient outcomes and won the 2025 Lasker Award.
Novo Nordisk’s Rybelsus® is now the first oral GLP-1 RA approved in Europe with cardiovascular benefit, following positive SOUL trial results. This milestone reshapes the GLP-1 landscape, combining oral convenience with outcomes data, and may accelerate adoption in China’s type 2 diabetes market.
Explore how large language models (LLMs) and AI co-scientists are revolutionizing hypothesis generation in molecular biology. Insights from recent Cell studies on cf-PICIs reveal AI’s potential to complement experimental research.
通过大语言模型和多智能体推理，AI Co-Scientist成功重现cf-PICIs的跨物种机制，凸显AI在分子微生物学中辅助假说生成与研究设计的潜力。
Sino–American Shanghai Squibb, established in 1982, was China's first Sino–U.S. pharmaceutical joint venture. This report delves into its legacy, challenges faced, and the anticipated transition under Hillhouse Capital.
中美上海斯贵宝成立于1982年，是中国首家中美合资制药企业。本文深入分析其历史遗产、面临的挑战以及预计在高瓴资本领导下的转型。
China’s HPV vaccine market is transforming in 2025, with NIP rollout, price wars among domestic manufacturers, and potential gains in cervical cancer prevention.
2025年全球制药业迎来产业快速转折：默沙东、礼来、阿斯利康在英国战略收缩，减肥药之王诺和诺德全球大幅裁员；中国创新药企恒瑞、三生制药等纷纷授权出海，与国际药企合作，重塑全球医药创新格局。
Merck’s UK exits, AstraZeneca’s paused investment, Lilly’s stalled Gateway Labs project, Novo Nordisk’s workforce cuts, and China’s record out-licensing deals with Hengrui and Pfizer/3SBio mark a turning point for the global pharmaceutical industry in 2025.
Baili Pharma has launched a head-to-head Phase III trial of BL-M07D1 versus Keytruda + chemo in first-line HER2-mutant NSCLC, a bold challenge to the current standard. Baili is also advancing Iza-Bren, an EGFR/HER3 ADC with strong Phase II results.
Maze Therapeutics’ SLC6A19 inhibitor MZE782 showed >40-fold phenylalanine excretion in Phase 1, advancing toward Phase 2 trials in PKU and CKD. The data position MZE782 as a potential best-in-class therapy for PKU and first-in-class option for CKD, directly challenging Jnana’s JNT-517.
KN026
China’s NMPA has accepted the NDA for Alphamab/CSPC’s KN026 (anbenitamab), the first domestic HER2 bispecific antibody to reach filing in gastric cancer. Backed by the KC-WISE Phase II/III trial, the drug could address a major gap in second-line HER2-positive gastric/GEJ adenocarcinoma.
daraxonrasib
Revolution Medicines unveiled updated clinical results for daraxonrasib in metastatic pancreatic cancer. Early Phase 1 data reveal 47% ORR as monotherapy and 55% in combination with chemotherapy, supporting a pivotal RASolute 303 phase 3 trial in first-line metastatic disease.
YolTech Therapeutics
YolTech Therapeutics has raised $45M in Series B funding to advance its in vivo CRISPR therapies. Lead candidate YOLT-101, for familial hypercholesterolemia, shows strong LDL-C reduction in early trials, with a Phase 3 study on the horizon—a milestone for Chinese gene editing.
BNT327
At WCLC 2025, pumitamig (BioNTech/BMS) demonstrated 76% ORR and 100% disease control in ES-SCLC, outperforming current PD-L1 monotherapies. The bispecific antibody combines checkpoint blockade and anti-angiogenesis for enhanced efficacy.
Pacibekitug
Novartis acquired Tourmaline Bio for $1.4B, gaining pacibekitug (TOUR006), a Phase 3-ready anti-IL-6 IgG2 mAb. Discovered via Pfizer and Medarex’s UltiMAb® platform, it shows up to 86% hs-CRP reduction and targets residual inflammatory risk in ASCVD.
SHR-8068
Hengrui’s CTLA-4 antibody SHR‑8068, licensed from CStone in a 1.3B RMB deal, is now in Phase III trials for lung cancer, competing in a space dominated globally by ipilimumab and tremelimumab. Innovent’s IBI310 is under review.
HLX17
hanghai Fosun Pharmaceutical is making strides in oncology with FDA approval for phase 1 trials of HLX17, a PD-1 biosimilar, and NMPA approval for phase 3 trials of SAF-189, an ALK/ROS1 inhibitor.
IDE849
IDEAYA and Hengrui’s IDE849 (SHR-4849) showed strong Phase 1 efficacy and manageable safety in relapsed/refractory SCLC at WCLC 2025. This report covers trial outcomes, CNS activity, dosing, licensing, regulatory status, and the DLL3 competitive landscape.
Iza-Bren
Iza-Bren (BL-B01D1) is a bispecific EGFR/HER3 ADC for EGFR-mutated NSCLC. At IASLC WCLC 2025, Phase II combo with osimertinib showed 100% ORR and 92% 12-mo PFS; monotherapy in pretreated patients had 66% ORR and 80% 12-mo OS, with manageable safety.
Ivonescimab
Summit Therapeutics’ Ivonescimab demonstrates statistically significant PFS improvement in the global HARMONi trial. OS did not meet the pre-specified threshold in the primary analysis, but longer follow-up in Western patients shows a nominal supportive trend for regulatory review.
DB-1303
DB-1303 (BNT323) achieved a positive Phase III readout in HER2-positive breast cancer, reinforcing DualityBio’s ADC platform and BioNTech’s oncology expansion beyond immunotherapy. The trial shows potential for global commercialization, including a planned China BLA filing.
HRS-1893
Hengrui’s HRS-1893, out-licensed to Braveheart Bio, enters the global oHCM race with aficamten and mavacamten. ESC 2025 Phase I showed safety and PK; Phase III (NCT07021976) is ongoing. This review covers HRS-1893 chemical structure, patents, preclinical PK, and trial data.